FDA Approves New Drug to Treat Progression of Alzheimer's Disease
June 21, 2021 | Strategic Insights for Ambulatory Care
What's the news. The first new treatment for Alzheimer's disease since 2003 was given accelerated approval on June 7, 2021, by the U.S. Food and Drug Administration (FDA). The FDA gave accelerated approval to Aduhelm, pending continued clinical trials, as the first therapy to target and affect the disease's underlying progression.